"lung cancer cell growth" trang 3 - tải miễn phí từ tailieunhanh
MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
14    49    0
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
9    63    0
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
6    94    0
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    87    1
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    65    1
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis
7    47    1
MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway

MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway
11    32    1
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study
8    48    1
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
8    59    1
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib
10    75    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer

Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
10    51    1
The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells

The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells
9    62    1
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study
10    17    1
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFRmutated, non–small cell lung cancer

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFRmutated, non–small cell lung cancer
8    6    1
Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements

Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements
12    6    1
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: A prospective observational study

Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: A prospective observational study
10    5    1
Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
12    5    1
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
6    8    1
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFRmutated non-small cell Lung cancer with brain metastases: A systematic review and meta-analysis

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFRmutated non-small cell Lung cancer with brain metastases: A systematic review and meta-analysis
11    3    1